Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

Introduction Hypertension is a significant risk factor in heart failure for worldwide patients.
More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Chronic kidney disease (CKD) is increasingly prevalent in patients with heart failure (HF)
and HF is one of the leading causes of hospitalisation, morbidity and mortality in patients …

Even with recent advances in care, heart failure remains a major cause of morbidity and
mortality, which urgently needs new treatments. One of the major antecedents of heart …

Chronic kidney disease (CKD) in heart failure (HF) patients is common, present in 49%, and
is associated with a higher mortality hazard ratio [2.34 (95% confidence interval 2.20–2.50); …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …